Laurie H. Sehn
劳里·塞恩
MD, MPH
Medical Oncologist; Clinical Associate Professor, University of British Columbia肿瘤内科医师；不列颠哥伦比亚大学临床副教授
👥Biography 个人简介
Laurie H. Sehn, MD, MPH is a foremost DLBCL clinician-researcher at BC Cancer Vancouver. She co-led the POLARIX phase III trial, which demonstrated that polatuzumab vedotin + R-CHP improved progression-free survival over R-CHOP in previously untreated DLBCL, making it the first major advance over R-CHOP in nearly two decades.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
POLARIX Trial and Frontline DLBCL
Co-principal investigator of POLARIX, the landmark phase III trial demonstrating pola-R-CHP superiority over R-CHOP as first-line therapy for intermediate- and high-risk DLBCL.
IPI and Prognostic Models in DLBCL
Contributed to refinement of the Revised International Prognostic Index (R-IPI) and other risk stratification models that guide treatment selection in newly diagnosed DLBCL.
Representative Works 代表性著作
Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma (POLARIX)
New England Journal of Medicine (2022)
Phase III trial showing pola-R-CHP improved PFS vs R-CHOP as first-line treatment for intermediate-/high-risk DLBCL.
The Revised International Prognostic Index (R-IPI): a better predictor of outcome for DLBCL
Blood (2007)
Landmark study redefining risk stratification in DLBCL patients treated with rituximab-based chemoimmunotherapy.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 劳里·塞恩 的研究动态
Follow Laurie H. Sehn's research updates
留下邮箱，当我们发布与 Laurie H. Sehn（BC Cancer, Vancouver Centre）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment